De novo fatty acid synthesis is a cancer therapy target and the drug Orlistat and several other drugs target the fatty acid synthase (FASN) enzyme while other cancer drugs target ATP citrate lyase (ACLY). The gene discussed is ACLY; the disease is cancer.